12 stories from 4 sources

Outbreak insecurity and cross-border drug bets define the day

Day’s Recap

Supporting Articles

10:25 AMStat News

An Ebola treatment center was burned down as the death toll in Congo passes 4,000

Summary

The Ebola outbreak in Congo has killed more than 4,000 people, while an Ebola treatment center was burned down amid efforts to contain the spread. The attack further disrupts care in an outbreak already described as the fastest-growing in history.

The destruction of a treatment center turns insecurity and public distrust into direct threats to

Why it matters

Epidemic control depends on public access and trust, both of which collapse when treatment sites become targets.

Link to Story

8:56 AMAl Jazeera

Ebola death toll surpasses 4,000 as DR Congo struggles to suppress outbreak

Summary

The Ebola death toll in the Democratic Republic of the Congo has surpassed 4,000 as authorities struggle to contain the outbreak. The burning of an Ebola-hit transit camp forced about 19,000 people to flee, underscoring the difficulty of maintaining an effective response.

The mass displacement shows that violence is expanding the outbreak's geographic and operational footprint. Evacuated

Why it matters

Displacement can turn a contained health emergency into a wider regional crisis by severing the systems needed to track and treat infections.

Link to Story

2 stories · 2 sources

8:31 AMCNBC

Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion

Summary

Western biopharma companies are increasingly licensing or acquiring drug candidates from Chinese developers as major products approach patent expiration. The shift reflects China’s growing role as a source of pharmaceutical innovation, not just manufacturing.

The patent cliff is pushing large drugmakers to buy external pipelines faster, and Chinese biotech

Why it matters

The next wave of blockbuster drugs may depend more heavily on cross-border deals with Chinese biotech companies.

Link to Story

2:47 AMBloomberg Markets

Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion

Summary

Novartis will license an mRNA-based autoimmune therapy from China’s Abogen Biosciences in a deal valued at up to $7.8 billion.

The agreement gives Novartis access to a Chinese-developed mRNA platform while giving Abogen capital and

Why it matters

The deal could accelerate mRNA treatments for autoimmune conditions and deepen reliance on cross-border Chinese biotech partnerships.

Link to Story

1:55 PMCNBC

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Summary

Eli Lilly and Novo Nordisk are developing amylin-based medicines as a new biological approach to treating obesity and diabetes. The drugs could complement or extend the effects of GLP-1 therapies.

The next competitive frontier in obesity treatment is shifting beyond GLP-1s toward drugs that activate

Why it matters

Amylin could reshape the obesity-drug market by giving patients alternatives to increasingly crowded GLP-1 treatments.

Link to Story

Other Developments

A curated list of other prominent stories from this day.

12:26 PMCNBC

Your health insurance premiums may take a big jump in 2027 — here's why

Summary

Experts expect many consumers to face health insurance premium increases of about 10% or more in 2027. Rising medical expenses and broader pressure on insurers are driving the projections.

A double-digit increase would push more of the healthcare cost burden onto households and employers.

Why it matters

Higher premiums could make coverage less affordable and accelerate tradeoffs over benefits, networks, and out-of-pocket costs.

Link to Story

11:00 AMStat News

Access to addiction meds for young people has improved — but retention hasn’t

Summary

More young people with opioid use disorder are receiving addiction medications, but only a small share starts treatment and few remain on it for long. A new study identifies retention as the central weakness in care.

The problem has shifted from access alone to continuity: prescribing has improved without producing durable

Why it matters

Short treatment duration limits the protective effect of medications during a period when young people face high overdose risk.

Link to Story

9:58 AMStat News

STAT+: Lilly bypasses Australian pharmacies with DTC model

Summary

Eli Lilly is launching LillyDirect in Australia to deliver Mounjaro directly to patients' homes. Australian doctors and pharmacists have criticized the model for bypassing traditional pharmacy channels.

Lilly's move shifts more of the prescribing and dispensing journey toward the manufacturer, giving it

Why it matters

Direct-to-consumer drug delivery could reshape how high-demand medicines reach patients and challenge the existing pharmacy system.

Link to Story

7:53 AMStat News

How big is Pennsylvania’s measles outbreak?

Summary

Pennsylvania’s fifth reported measles death has renewed questions about the scale of the state’s outbreak and its connection to wider transmission across the country. The full size of the outbreak remains difficult to establish from the available reporting.

The fifth death confirms that the outbreak is producing severe consequences, while uncertainty about case

Why it matters

The outbreak shows how declining or uneven measles vaccination coverage can turn a preventable disease into a persistent public-health threat.

Link to Story

4:30 AMStat News

STAT+: NIH awarded all its grant funding, but delayed and opaque decisions stymied researchers

Summary

The NIH awarded its available grant funding for fiscal 2026, but researchers faced delays and limited visibility into how decisions were made. Grants involving health disparities, race, and ethnicity continued to decline, while other administration priorities showed little progress.

The central shift is not a funding shortfall but an increasingly unpredictable allocation process. Researchers

Why it matters

Unclear funding priorities can reshape the research pipeline before Congress or the public sees a formal budget cut.

Link to Story

4:30 AMStat News

Opinion: The law has to catch up on orphan-designated drugs with multiple uses

Summary

A pharmacist argues that federal law and the 340B drug discount program have not kept pace with orphan-designated medicines that serve multiple uses. The result is uncertainty over how discounts should apply when a drug’s indications extend beyond its original rare-disease designation.

The legal problem is that a designation built around one rare condition can govern a

Why it matters

Clearer rules would determine whether 340B savings follow the drug’s designation or the specific use for which it is prescribed.

Link to Story

4:30 AMStat News

Opinion: I treated heat stroke at the NYC Marathon. Marathons need to prepare for a climate-changed world

Summary

A physician who treated heat stroke at the New York City Marathon calls for evidence-based medical plans for extreme heat. The argument is that race organizers must adapt preparation and emergency response to worsening heat risks.

Extreme heat is turning marathon medicine from a contingency issue into a core planning requirement.

Why it matters

Climate-driven heat raises the risk of preventable illness and makes medical preparedness central to whether mass races can be safely held.

Link to Story

Make it yours

Build Your First Pass.

Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!